2 posts tagged by Digg
Science
A post describing the UK-led NEOPRISM-CRC trial says patients with stage 2 or 3 mismatch repair-deficient bowel cancer received nine weeks of pembrolizumab immunotherapy before surgery.
Science
A science and health roundup highlights the reported survival benefit alongside other lung cancer results, including a combination therapy that missed its endpoints.